US Drug Patent 12,109,197: Scope, Claims, and US Patent Landscape
US Patent 12,109,197 (the “’197 patent”) is directed to a combination dosing regimen for treating or preventing uncomplicated urinary tract infection (UTI) using a β-lactam plus probenecid, with defined dose ranges, timing, and duration, and with method claims that extend into oral and co-formulation use.
What is the core claim scope of US 12,109,197?
Independent claim 1 defines a regimen-based combination
Claim 1 is a method claim. It requires all elements below:
- Indication: treating or preventing uncomplicated UTI
- Patient: a subject in need thereof (human limitation appears in dependent claim 6)
- β-lactam component:
- 400 mg to 600 mg of a β-lactam compound or a pharmaceutically acceptable salt
- Probenecid component:
- 400 mg to 600 mg of probenecid or a pharmaceutically acceptable salt
- Dosing schedule:
- simultaneously
- twice daily (BID)
- Duration:
Claim 1 also requires the β-lactam compound be one of the specific β-lactams listed in the claim text. Your excerpt shows the list as blanks (“: or …”), so the exact β-lactam identities are not recoverable from the provided text. The scope therefore cannot be mapped to specific active moieties beyond “a β-lactam from the claim’s enumerated set.”
Claim 1 is the center of gravity: most downstream claims narrow only formulation or administration mode or specify subsets of duration.
Dependent claims narrow administration mode and formulation
Key dependent claims you provided:
- Claim 2 (oral administration): both β-lactam and probenecid are administered by oral administration.
- Claim 3 (oral co-formulation): an oral co-formulation containing both components is administered.
- Claim 4 (tablet): the co-formulation is a tablet.
- Claim 5 (food effect): a food is administered during dosing.
- Claim 6 (human): subject is a human.
- Claims 10 (duration subset): dosing is for 5 days.
Claims 7-9 further specify the β-lactam selection from the enumerated group, but again the β-lactam identities are missing from the excerpt.
How broad is the claimed dosing and regimen?
Dose band for both components
Claim 1 requires each component to fall within the same numeric band:
| Parameter |
Claim requirement |
| β-lactam dose |
400 mg to 600 mg per administration |
| Probenecid dose |
400 mg to 600 mg per administration |
| Simultaneity |
both administered simultaneously |
| Frequency |
twice daily |
| Treatment/prevention window |
5 to 10 days |
This structure is important for freedom-to-operate (FTO): a competitor can potentially avoid literal infringement by shifting either (a) dose outside the band, (b) schedule so drugs are not simultaneous, or (c) duration outside 5–10 days. Non-literal infringement risk remains if equivalents are argued, but the numeric constraints create a clear boundary for claim construction and design-around.
Duration sensitivity
Claim 1 spans 5–10 days, while claim 10 locks one commercially attractive endpoint at 5 days. This means:
- A 5-day regimen faces heightened literal risk.
- A regimen of 7 or 10 days remains within claim 1 but does not land within claim 10’s added limitation (unless equivalents are asserted).
What does the patent protect in practice: drug product vs method?
It is a method claim, not a composition claim
All provided claims are method of treatment steps:
- administering defined doses,
- simultaneously,
- at defined frequency,
- for defined duration.
Dependent claims bring in administration details:
- oral dosing (claim 2),
- oral co-formulation (claim 3),
- tablet dosage form (claim 4),
- food taken during administration (claim 5).
Even where a “tablet” is recited (claim 4), it is still framed as “a method… wherein … is administered.” That typically means enforcement focuses on how a product is used (and how it is prescribed and taken) rather than on the mere existence of a tablet composition.
Co-formulation language narrows to use of an oral combined product
Claim 3 requires an oral co-formulation comprising both β-lactam and probenecid. That narrows infringement theories versus a scenario where a clinician prescribes:
- β-lactam tablets separately plus probenecid tablets separately.
Claim 2, however, is broader in that it permits separate oral administration, as long as dosing is simultaneous at the same BID schedule and doses fall in the 400–600 mg bands.
What is the technical “hook”: probenecid to modify β-lactam exposure
The claim structure indicates a strategy of pairing a β-lactam with probenecid at relatively high doses (400–600 mg BID dosing range per administration) to treat uncomplicated UTI for short courses (5–10 days). From a patent-landscape standpoint, this claim format is designed to capture:
- regimen-level innovations (dose, schedule, duration),
- and formulation convenience (co-formulation, tablet).
The key legal consequence is that the claim is not limited to one administration schedule outside the tight numeric window. It is also not limited to a single β-lactam moiety outside the claim’s enumerated set.
Where are the likely infringement boundaries?
Because the claims are numeric and scheduling-based, infringement can pivot on a few concrete levers:
1) Dose outside 400–600 mg
- Literal risk decreases if either component is dosed below 400 mg or above 600 mg per administration.
- Claim 1 explicitly bounds both.
2) “Simultaneously” and BID
- If probenecid is given with a time offset such that it is not “simultaneously,” a literal argument exists that the step requirement is not met.
- Altering to TID or once daily is also a design-around path.
3) Duration
- Claim 1 covers 5–10 days.
- A design that uses, for example, 3 days or 11+ days avoids claim 1 literal duration, though it may still be assessed under other patents or clinical rationale.
4) Oral route
- If dosing is non-oral, claim 2 and dependent formulation claims become harder to assert.
- Claim 1 itself does not explicitly require oral administration, but dependent claims do.
5) Co-formulation and tablet
- A combined tablet product implicates claim 3 and claim 4 more directly.
- Separate oral dosing products implicate claim 2 more directly, if simultaneity and dose band conditions are met.
Dependent claims: how they change the business risk
Claim 2 (oral route)
Market impact: oral UTI regimens are a major commercial segment. Claim 2 increases practical enforcement leverage against an oral regimen using both components.
Claim 3 and Claim 4 (co-formulation and tablet)
These claims matter if a sponsor develops a fixed-dose combination tablet. If a partner keeps probenecid separate, those dependent claims may not be met, but claim 2 still may.
Claim 5 (food during administration)
This is a narrower condition: it adds a timing behavior of the patient during dosing. Enforcement would require evidence that food was administered during dosing as claimed. It can function as an “extra hook” but is often harder to prove than core dosing steps.
Claim 10 (5-day course)
This claim is a narrower subset of claim 1. It increases enforcement leverage for very short courses that match common UTI treatment patterns.
What does the missing β-lactam list mean for landscape mapping?
Claims 7-9 and claim 1 refer to specific β-lactam compounds by name, but the provided excerpt shows the identities as blanks. That prevents a definitive mapping of:
- which exact β-lactam(s) are covered,
- which competitor drugs are within scope,
- and which existing UTI β-lactams might be safer outside the enumerated set.
However, the structural scope still can be analyzed:
- the β-lactam must be one of the listed options;
- the dose and regimen requirements remain operative regardless of which particular β-lactam is chosen from the claim text.
US patent landscape: how to position the ’197 patent in competitive planning
Landscape structure you should assume for this category
For combination UTIs using β-lactams plus probenecid, the landscape typically clusters into:
- Active ingredient patents (β-lactam specific, probenecid use/formulation)
- Method-of-use patents (UTI or other infections, with dose regimen and/or patient subsets)
- Fixed-dose combination patents (co-formulation, tablet, oral combination)
- Regimen optimization patents (short-course duration, BID scheduling, simultaneity)
- Manufacturing and formulation patents (tableting, release profiles)
Given the claim style of ’197, it most likely sits in buckets (2), (3), and (4): a method-of-treatment claim with a co-formulation dependent layer.
How claim 1 typically affects FTO strategy
- If an active β-lactam product already exists and probenecid is co-administered in similar dose and duration, ’197 can become a “use” risk even if composition freedom exists.
- If a sponsor wants to market a new fixed-dose combination tablet with probenecid and a claim-listed β-lactam, then claims 3 and 4 become central.
What matters for investors
The commercializable wedge for ’197 is not just “β-lactam + probenecid,” but:
- 400–600 mg bands for both agents,
- simultaneous BID dosing,
- 5–10 day short course,
- oral and potentially tablet fixed-dose combination.
That combination of specifics often limits the universe of potential literal infringement products but can still cover a real-world regimen if clinicians follow the claimed schedule.
Claim charts: where infringement arguments will concentrate
Below is a practical mapping of claim 1 elements to real-world prescribing behavior.
| Claim 1 element |
What must be done in the real regimen |
| Treat/prevent uncomplicated UTI |
Indication on label or off-label use in clinical record |
| β-lactam 400–600 mg |
β-lactam strength per dose within range |
| Probenecid 400–600 mg |
Probenecid per dose within range |
| Simultaneous |
Administer at the same time point (or same dosing event) |
| BID |
Morning and evening dosing (or equivalent schedule) |
| Duration 5–10 days |
Treatment course length matches window |
Dependent layer (for higher enforcement likelihood):
- Oral administration: route must be oral (claim 2).
- Co-formulation/tablet: product must combine both ingredients (claims 3-4).
- Food: food is taken during administration (claim 5).
Key Takeaways
- US Patent 12,109,197 is a method-of-treatment patent for uncomplicated UTI using a β-lactam + probenecid regimen.
- Claim 1 is regimen-constrained: 400–600 mg of each component, simultaneously BID, for 5–10 days.
- Dependent claims narrow enforcement to oral dosing, fixed-dose oral co-formulation, tablet, food timing, and a 5-day course.
- The primary design-around levers are dose bands, simultaneity, frequency (BID), and duration; co-formulation claims turn on whether a combined tablet is used.
FAQs
1) Is US 12,109,197 a composition patent?
No. The provided claims are framed as methods of treating or preventing uncomplicated UTI using specific administration steps.
2) What dosing schedule does claim 1 require?
Both the β-lactam and probenecid must be administered simultaneously twice daily for 5 to 10 days.
3) What dose ranges are explicitly claimed?
Claim 1 requires 400 mg to 600 mg per dose for both the β-lactam and probenecid (each as compound/salt).
4) What additional scope do dependent claims add?
Dependent claims add oral route (claim 2), oral co-formulation (claim 3), tablet (claim 4), food during administration (claim 5), human use (claim 6), and a 5-day course (claim 10).
5) How can a developer reduce literal infringement risk?
By moving outside at least one of the critical claim constraints: dose band, simultaneity, BID frequency, duration window, or oral/co-formulation limitations for dependent claims.
References
[1] United States Patent No. 12,109,197. Claims provided in user prompt.
